Research Articles Library
Literature Analysis Tools
Advanced Search
Filter by PMID, year, source, DOI and other criteria
Literature Analysis
Analyze research trends and hotspots
Batch Export
Export search results to Excel/PDF
Extracellular Vesicles Delivered by a Nanofiber-Hydrogel Composite Enhance Healing In Vivo in a Model of Crohn's Disease Perianal Fistula
Publication Year: 2025 Source: Adv Healthc Mater PMID: 39240055
No Abstract
Novel Microbial Engraftment Trajectories Following Microbiota Transplant Therapy in Ulcerative Colitis
Publication Year: 2025 Source: J Crohns Colitis PMID: 39240145
BACKGROUND AND AIMS: Microbiota transplant therapy (MTT) is an emerging treatment for ulcerative colitis (UC). One proposed mechanism for the benefit of MTT is through engraftment of donor microbiota; however, engraftment kinetics are unknown. We identified SourceTracker as an efficient method both to determine engraftment and for the kinetic study …
Thromboprophylaxis in pediatric inflammatory bowel disease: Is it time to reframe the guidelines?
Publication Year: 2025 Source: Indian J Gastroenterol PMID: 39240509
No Abstract
Disease burden of patients with moderate to severe ulcerative colitis: A French multicenter real-life study (THEFAR)
Publication Year: 2025 Source: Dig Liver Dis PMID: 39242250 DOI: 10.1016/j.dld.2024.08.044
BACKGROUND: Specific studies on the impact of ulcerative colitis (UC) and bowel urgency (BU) on disability and quality of life (QoL) of patients on advanced therapies are missing. METHODS: Clinical and therapeutic management data were collected by Gastroenterologists from adult patients with UC treated with advanced therapies. Patients reported outcomes …
Differences in the Adverse Event Burden of Corticosteroid Use in Inflammatory Bowel Disease as Reported Between Adverse Event Reporting Systems and a Patient Questionnaire
Publication Year: 2025 Source: J Crohns Colitis PMID: 39243391 DOI: 10.1093/ecco-jcc/jjae138
BACKGROUND AND AIMS: Corticosteroids are widely used in managing inflammatory bowel disease (IBD). While adverse events (AEs) of corticosteroids are well recognized, current understanding of corticosteroid-related AE burden in IBD remains incomplete. METHODS: AE reports for prednisone/prednisolone and budesonide were extracted from the Food and Drug Administration Adverse Event Reporting …
A mathematical framework for genetic relatedness analysis involving X chromosome aneuploidies
Publication Year: 2025 Source: Forensic Sci Int Genet PMID: 39243525 DOI: 10.1016/j.fsigen.2024.103128
The unique features of the X chromosome can be crucial to complement autosomal profiling or to disentangle complex kinship problems, providing in some cases a similar or even greater power than autosomes in paternity/maternity investigations. While theoretical and informatics approaches for pairwise X-linked kinship analyses are well established for euploid …
Population-specific differences in the human microbiome: Factors defining the diversity
Publication Year: 2025 Source: Gene PMID: 39244168
No Abstract
Fecal urgency and incontinence in inflammatory bowel disease perceived by physician and patient: Results from the Swiss fecal urgency survey
Publication Year: 2025 Source: United European Gastroenterol J PMID: 39246002 DOI: 10.1002/ueg2.12657
INTRODUCTION: Although increasingly appreciated, little is known about the prevalence of fecal urgency, fecal incontinence and differences between patients' and physicians' perception in inflammatory bowel disease (IBD). METHODS: We performed an online patient and physician survey to evaluate the assessment, prevalence and impact of fecal urgency and incontinence in IBD. …
Amlexanox targeted inhibition of TBK1 regulates immune cell function to exacerbate DSS-induced inflammatory bowel disease
Publication Year: 2025 Source: Clin Exp Immunol PMID: 39248363 DOI: 10.1093/cei/uxae082
Amlexanox (ALX) is a small-molecule drug for the treatment of inflammatory, autoimmune, metabolic, and tumor diseases. At present, there are no studies on whether ALX has a therapeutic effect on inflammatory bowel disease (IBD). In this study, we used a mouse model of dextran sulfate sodium-induced colitis to investigate the …
Comparative Efficacy of Novel Biologics, Anti-tumor Necrosis Factor Agents, and Immunomodulators to Prevent Postoperative Recurrence in Crohn's Disease: A Systematic Review and Network Meta-analysis
Publication Year: 2025 Source: J Crohns Colitis PMID: 39249143
BACKGROUND AND AIMS: Our objective was to compare the efficacy of novel biologics (such as vedolizumab and ustekinumab), anti-tumor necrosis factor (anti-TNF) agents, and immunomodulators (IMMs) in preventing postoperative recurrence (POR) of Crohn's disease (CD). METHODS: We searched the PubMed, Embase, and the Cochrane Library databases up to December 2023 …
Need more literature?
The current database contains 98453 research articles. If you need to search for more literature or perform AI analysis, please use our knowledge acquisition module or explore external literature resources.
External Resources: Access comprehensive literature databases worldwide